scholarly journals Safety and efficacy of prostatic artery embolization for large benign prostatic hyperplasia in elderly patients

2021 ◽  
Vol 49 (1) ◽  
pp. 030006052098628
Author(s):  
Chen Xu ◽  
Gang Zhang ◽  
Jin-jin Wang ◽  
Chun-xian Zhou ◽  
Min-jun Jiang
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Elderly Patients ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Antigen Level ◽  
Residual Urine Volume ◽  
Safety And Efficacy ◽  
Total Prostate Specific Antigen

Objective To assess the safety and efficacy of prostatic arterial embolization (PAE) for elderly patients with lower urinary tract symptoms secondary to large benign prostatic hyperplasia. Methods Twenty-eight patients (>80 years of age) with prostate volume >80 mL were enrolled from October 2016 to October 2019. PAE was performed using microspheres and functional results were evaluated at 1, 3, 6, and 12 months postoperatively. The following data were recorded: International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urine flow rate (Qmax), post-void residual urine volume, prostate volume and total prostate-specific antigen level. Results Selective prostatic arterial catheterization and embolization were achieved in 27 of 28 patients. Follow-up data were available for those 27 patients until 12 months postoperatively. Significant improvements were found at all postoperative time points in terms of the mean IPSS, mean QoL score, mean Qmax, mean post-void residual urine volume, mean total prostate-specific antigen level, and mean prostate volume. The overall complication rate was 46.4%. Conclusions PAE is an efficacious and safe treatment for elderly patients with large prostate volume; it may offer an effective approach for patients who are not candidates for open or endoscopic surgical procedures because of comorbidities.

scholarly journals 15 years’ survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression

2018 ◽  
Vol 86 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Andrey Zinovievich Vinarov ◽  
Leonid Grigorievich Spivak ◽  
Darina Vladimirovna Platonova ◽  
Leonid Mikhailovich Rapoport ◽  
Dmitry Olegovich Korolev
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Plant Extract ◽  
Prostate Volume ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Term Therapy ◽  
Serenoa Repens ◽  
Residual Urine Volume ◽  
Residual Urine ◽  
Study Results

Aim: The aim of this study is to investigate the efficacy and safety of long-term therapy with Serenoa repens extract with regard to halting benign prostatic hyperplasia progression. Material and methods: An open non-comparative observational study of the continuous use of S. repens plant extract at a dosage of 320 mg once a day for 15 years was performed in 30 patients at risk for benign prostatic hyperplasia progression. Changes in IPSS (International Prostatic Symptoms Scale) and QoL (Quality of life) scores and changes in Qmax, voided volume, residual urine volume, and prostate volume were evaluated during the study. Results: The study showed an absence of progression based on both subjective (the sum of scores on the IPSS and QoL scales) and objective (prostate volume, urination rate, residual urine volume) criteria. Furthermore, the patients had no adverse events related to the study drug, including prostate cancer. Conclusions: The 15 years’ study results suggest that taking S. repens plant extract continuously at a daily dose of 320 mg is an effective and safe way to prevent the progression of benign prostatic hyperplasia.

scholarly journals CORRELATION BETWEEN SERUM TISSUE POLYPEPTIDE SPECIFIC ANTIGEN Level AND PROSTATE VOLUME IN BPH

2018 ◽  
Vol 23 (2) ◽  
pp. 141
Author(s):  
Mahrany Graciella Bumbungan ◽  
Endang Retnowati ◽  
Wahjoe Djatisoesanto
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Transrectal Ultrasonography ◽  
Antigen Level

Volume prostat menjadi informasi yang penting karena dapat memperkirakan kematian pada Benign Prostatic Hyperplasia (BPH).Volume prostat diukur menggunakan TRUS (Transrectal Ultrasonography) sebagai baku emas namun TRUS mempunyai beberapakekurangan. Dibutuhkan suatu tolok ukur lain yang dapat memperkirakan volume prostat. Tissue Polypeptide Specific Antigen (TPS)yang terdeteksi di peredaran terdiri dari fragmen sitokeratin yang terdapat dalam jaringan dan menunjukkan status proliferasi. Selepitel di BPH yang mengandung sitokeratin 18 akan mengalami hiperplasia sehingga dapat terdeteksi dengan pemeriksaan TPS. Tujuanpenelitian ini adalah membuktikan adanya kenasaban antara kadar TPS serum dan volume prostat. Subjek penelitian terdiri dari 28pasien BPH yang datang berobat ke Poli Rawat Jalan Urologi RSUD Dr. Soetomo Surabaya. Volume prostat diukur menggunakan alatTRUS. Kadar TPS serum diukur menggunakan metode ELISA (TPS® ELISA IDL Biotech). Kadar TPS serum berkisar antara 82,45–1771,5U/L (195,35±349,79 U/L). Volume prostat beragam antara 20,7-87,4 cm (34,70±15,31 cm). Tidak terdapat kenasaban positif yangbermakna antara kadar TPS serum dan volume prostat (p=0,404; r=0,164).

scholarly journals Comparison of α-Blocker Monotherapy and α-Blocker plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment of Benign Prostatic Hyperplasia

2012 ◽  
Vol 40 (3) ◽  
pp. 899-908 ◽  
Author(s):  
K-J Joo ◽  
W-S Sung ◽  
S-H Park ◽  
W-J Yang ◽  
T-H Kim
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Combination Therapy ◽  
Reductase Inhibitor ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Urinary Flow ◽  
Volume Transition ◽  
Postvoid Residual Urine

OBJECTIVE: This study compared α-blocker monotherapy with combination therapy involving an α-blocker and a 5-α reductase inhibitor for benign prostatic hyperplasia (BPH), according to baseline prostate volume. METHODS: Korean men diagnosed with BPH were randomized to 12 months' treatment with 0.2 mg tamsulosin or 0.2 mg tamsulosin plus 0.5 mg dutasteride. Prostate specific antigen (PSA), prostate volume, transition zone volume (TZV), International Prostate Symptom Score (IPSS), maximal urinary flow rate ( Qmax), postvoid residual urine volume and sexual function were assessed at baseline and after 12 months' treatment. Variables were analysed based on baseline prostate volumes of ≤ 35 ml or > 35 ml. RESULTS: In total, 216 men with BPH were included. Combination therapy resulted in significant improvements in prostate volume, TZV, PSA, IPSS and Qmax, which were most pronounced in men with a prostate volume > 35 ml. CONCLUSIONS: Tamsulosin monotherapy was sufficient treatment for BPH in Korean men with a prostate volume ≤ 35 ml. Combination tamsulosin and dutasteride therapy provided greater benefits than tamsulosin monotherapy in men with BPH whose prostate volume was > 35 ml.

Superselective prostatic artery embolization in the treatment of large benign prostatic hyperplasia

2021 ◽  
pp. 039156032199359
Author(s):  
Alexander Izrailevich Neymark ◽  
Andrey Anatoljevich Karpenko ◽  
Boris Alexandrovich Neymark ◽  
Mikhail Alexandrovich Tachalov ◽  
Denis Dmitrievich Arzamastsev ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Urine Volume ◽  
Symptom Burden ◽  
Prostatic Hyperplasia ◽  
Artery Embolization ◽  
Prostatic Artery Embolization ◽  
Symptomatic Benign Prostatic Hyperplasia ◽  
Prostatic Artery

Purpose: To evaluate the use of prostatic artery embolization (PAE) as a treatment option for patients with symptomatic benign prostatic hyperplasia (BPH) with prostate volumes of 80 cc and more. Materials and Methods: The study included 75 patients with high anesthesia-related risks for conventional surgery (TURP). All patients were surveyed for symptom burden, using IPSS and quality of life score. The prostate volume was determined by transrectal ultrasonography (TRUS). At baseline, prostate-specific antigen (PSA) level was obtained in all patients. Urodynamics was evaluated using uroflowmetry. Clinical outcomes were assessed at follow-up 1, 3, 6, 12, and 24 months after PAE. Results: The prostate volume decreased significantly at months 1 and 3 post-treatment; the prostate continued shrinking until month 12, and the size was then stabilized. At month 24, prostate volume decreased by 40.82%, from 134.0 ± 8.3 mL at baseline to 79.3 ± 6.6 mL. Postvoid residual (PVR) urine volume was significantly decreased from 55.9 ± 5.3 mL to 22.0 ± 1.8 mL 1 month after PAE ( p < 0.001). Qmax increased from 9.2 ± 0.3 mL/s to 15.7 ± 0.4 mL/s. IPSS score following PAE decreased from 28.2 ± 0.7 to 9.7 ± 0.8 ( p < 0.001). QoL improvement was observed from 4.8 ± 0.2 at baseline to 1.8 ± 0.2 at month 24 ( p < 0.001). Decreased activity and density of adenomatous tissue resulted in decreased total PSA levels: from 5.9 ± 1.1 ng/mL to 2.6 ± 0.2 ng/mL ( p < 0.001). TURP became feasible in 35 patients due to reduction of prostate volumes below 80 mL after PAE. Conclusions: PAE was effective in relieving LUTS and reducing prostate size, and may be considered as a preoperative approach for patients with large prostate.

Relationship of Prostate-Specific Antigen and Prostate Volume in Korean Men with Biopsy-Proven Benign Prostatic Hyperplasia

Urology ◽  
2008 ◽  
Vol 71 (3) ◽  
pp. 395-398 ◽  
Author(s):  
Sang Eun Lee ◽  
Jae Seung Chung ◽  
Byung Kyu Han ◽  
Ki Hyuk Moon ◽  
Sung Il Hwang ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostate Specific Antigen ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Relationship Of
Sign in / Sign up

Export Citation Format

Share Document